BWAY - BrainsWay Sales Growth YoY (TTM)

Graphic logo of BrainsWay Ltd (BWAY)

Stable cash flows at BrainsWay Ltd. are supported by the diversified distribution of neurostimulators. Annual operating revenue growth (TTM) confirms this resilience, and 31.90 becomes the new value for this metric. High R&D expenditures and H-coil patents block competitor entry, although pressure is mounting from new antidepressants and medtech behemoths in the growing non-invasive therapy niche.

BrainsWay Ltd. (BWAY) Revenue Growth YoY (Last 12 Months): for the period 02/11/2024 - 11/18/2026

BrainsWay - analytical breakdowns and key metrics (BWAY)

- current quotes and average value forecast:
Summary company analytics:BrainsWay Ltd - BWAY
Manufactured products of brainsway.com

For BrainsWay Ltd., whose neurostimulation systems remain in demand regardless of economic cycles, this metric reflects the real dynamics of market demand for TMS therapy. By analyzing the LTM sales volume trend, an investor can see the consensus revenue estimate for the trailing twelve months, which allows for the identification of dangerous discrepancies between actual sales and accounting profit, thereby minimizing the risk of capital losses.